NASDAQ · Financial Statements
Allena Pharmaceuticals, Inc. (ALNA) Financial Statements
$0.08
NASDAQ: ALNA
Overview Financials Dividend Allena Pharmaceuticals, Inc. most recently reported annual revenue of $0, a net loss of $33.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2017 2018 2019 2020 2021 Revenue $0 $0 $0 $0 $0 Operating Profit $-21.0M $-36.0M $-47.0M $-32.0M $-32.0M Net Profit $-22.0M $-36.0M $-47.0M $-33.0M $-33.0M EPS $-4.79 $-1.72 $-2.13 $-1.01 $-1.03 Op Margin — — — — —
Balance Sheet (USD)
Metric 2017 2018 2019 2020 2021 Total Assets $96.0M $65.0M $34.0M $39.0M $35.0M Total Liabilities $13.0M $16.0M $17.0M $16.0M $16.0M Cash $94.0M $62.0M $30.0M $35.0M $30.0M Borrowings $9.0M $10.0M $10.0M $10.0M $1.0M
Cash Flow (USD)
Metric 2017 2018 2019 2020 2021 Operating Cash Flow $-21.0M $-32.0M $-44.0M $-28.0M $-46.0M Investing Cash Flow $23.0M $-1.0M $0 $-1.0M $-1.0M Financing Cash Flow $67.0M $-1.0M $12.0M $34.0M $41.0M Net Cash Flow $69.0M $-33.0M $-32.0M $5.0M $-5.0M Free Cash Flow $-21.0M $-32.0M $-44.0M $-29.0M $-46.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.00 EV / EBITDA 0.92 FCF Yield — Quick Ratio 2.11 Interest Coverage -63.40 Return 1Y — Return 3Y — Return 5Y —
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .